Y Intercept Hong Kong Ltd Sells 6,875 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

Y Intercept Hong Kong Ltd decreased its holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) by 23.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,684 shares of the company’s stock after selling 6,875 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Wave Life Sciences were worth $281,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Wave Life Sciences by 23.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock worth $37,000 after purchasing an additional 856 shares in the last quarter. Kraematon Investment Advisors Inc. raised its position in Wave Life Sciences by 24.3% in the 4th quarter. Kraematon Investment Advisors Inc. now owns 19,885 shares of the company’s stock worth $246,000 after purchasing an additional 3,885 shares during the last quarter. KBC Group NV acquired a new position in Wave Life Sciences during the 4th quarter worth $67,000. US Bancorp DE boosted its position in Wave Life Sciences by 53.9% in the 3rd quarter. US Bancorp DE now owns 18,043 shares of the company’s stock valued at $148,000 after buying an additional 6,316 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in shares of Wave Life Sciences by 6.8% in the 4th quarter. New York State Common Retirement Fund now owns 109,084 shares of the company’s stock valued at $1,349,000 after buying an additional 6,900 shares during the period. Institutional investors and hedge funds own 89.73% of the company’s stock.

Wave Life Sciences Price Performance

Shares of NASDAQ:WVE opened at $11.23 on Wednesday. Wave Life Sciences Ltd. has a 1 year low of $4.25 and a 1 year high of $16.74. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -10.12 and a beta of -1.09. The company’s 50 day simple moving average is $11.63 and its 200 day simple moving average is $11.19.

Analysts Set New Price Targets

Several brokerages have recently commented on WVE. Mizuho lifted their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Truist Financial upped their target price on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. Jefferies Financial Group assumed coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They issued a “buy” rating and a $26.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective on shares of Wave Life Sciences in a report on Wednesday, November 13th. Finally, StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Thursday, February 27th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.60.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.